Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486485 | 0.89 | KIT (0.36) | KITMAP4K4ALDH1A1 | |
| SCHEMBL19486477 | 0.86 | KCNH2 (0.38) | KITHRH3TGFBR1ACVR1KCNH2 | |
| SCHEMBL19486329 | 0.86 | CHRNA7 (0.44) | KITKHKMAP4K4KDM4EMAPT | |
| SCHEMBL19486469 | 0.85 | BMP4 (0.46) | KITKHKMAP4K4TGFBR1ACVR1 | |
| SCHEMBL19486399 | 0.85 | KIT (0.37) | KITHRH3TGFBR1ACVR1KCNH2 | |
| SCHEMBL19486444 | 0.83 | KIT (0.42) | KITMAP4K4KDM4EALDH1A1MAPT | |
| SCHEMBL25799845 | 0.83 | OPRM1 (0.35) | KIT | |
| SCHEMBL19486752 | 0.83 | BMPR1B (0.38) | KITHRH3TGFBR1ACVR1KCNH2 | |
| SCHEMBL19486330 | 0.83 | BMPR1B (0.38) | KITHRH3TGFBR1ACVR1KCNH2 | |
| SCHEMBL25768303 | 0.82 | MAP4K4 (0.39) | KITKHKHRH3MAP4K4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KIT 27/4885KHK 2328/4885HRH3 2988/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KIT 189/4885KHK 2037/4885HRH3 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.